EVFOUNDRY - HansaBioMed Life Sciences Ltd

HansaBioMed Life Sciences Ltd is a company entirely dedicated to research and development of products in the field of exosome sciences.
Our mission is to develop and commercialize proprietary platforms, kits, reagents and equipment for exosomes research in the Life Science market.
HansaBioMed Life Sciences is a world-wide pioneer in releasing the catalogue featuring the widest choice and selection of products dedicated to exosome research available on the global Life Science market. The portfolio includes lyophilized exosomes from numerous cell lines and body fluids, exosome purification tools, EV binding antibodies and kits for enrichment and quantification of specific exosome subpopulations and of scpecific EV shuttled molecules (proteins, RNAs and DNA). Beside catalogue products HansaBioMed Life Sciences is actively offering custom product and service based projects, extending the capacities and translating EV based approaches to novel and advanced biomedical applications. To this purpose the company collaborates with leading international research groups, both academic and industrial, to further develop and implement technologies and standards in the field.

RESEARCH ACTIVITY

HBM Research Projects:

FP7 CIRTUMAN: Characterization of new tumour markers and development of a new diagnostic tool for cancer based on circulating microvesicles. Coordinator
FP7 EXOID: Purification, quantification and characterisation of exosomes from body fluids for preclinical and clinical applications. Coordinator
FP7 COST Action (BM1202) Biomedicine and Molecular Biosciences: European Network on Microvesicles and Exosomes in Health and Disease. national MC member
Children Tumor Foundation Clinical Research Award 2013-2014: #2013-04-002, "Identification of neurofibroma and MPNST specific exosome-associated markers as early detectors of malignant transformation."
TRANSCAN-2-Translational research on human tumour heterogeneity to overcome reccurence and resistance to therapy. "Cancer evolution and identification of relapse-initiating cells-CEVIR"
TRAIN-EV: H2020-MSCA-ITN-2016. Aim: to "provide excellent and integrated multi-disciplinary and inter-sectoral training of a critical mass of ESRs of outstanding potential in the academic, clinical, and industry/business components of exploiting EV, while performing novel cutting-edge research to address these gaps and generate new knowledge".
INDEX: H2020-FETOPEN-1-2016-2017. Aim: to “isolate and characterize exosomes available in body fluids through development and integration of novel technological breakthroughs and accelerate the transition of exosome-based research and scientific discoveries to real clinical utility”. Funded by the European Commission in the framework of H2020 FET-OPEN programs.
EXIT: EURONANOMED III. Joint Transnational call for proposals (2017) for "European Innovative Research and Technological Development Projects in Nanomedicine". Aim: to "develop a beyond the state-of-the art nanotechnology driven analytical platform for isolation of exosomes and use this platform to investigate metabolic, proteomic, immunologic and transcriptional changes in AD".

evFOUNDRY PROJECT CONTRIBUTION

HBM-LS will be dedicated to the exploitation, dissemination, and communication of results, training of young scientists and operators in new skills, connecting with the relevant actors in the current international and EU research scenes and paying attention, supported by Lonza, to plan a future EU industrial roadmap beyond the TRL 2-3 that evFOUNDRY will achieve. In particular, within the project, HBM-LS specifies and offers the standards and referent methods and assays for set-up and bench-marking of novel protocols and devices in the projects’s pipeline.
HBM-LS will also test the integrated evFOUNDRY modular-system for its processing performance metrics and implement a lab-scale prototype for a scale-up production of quality-compliant immunomodulatory EVs.

SELECTED PUBLICATIONS

A new method to measure and characterize microvesicles in the human body fluids – AU2009207927 (A1) (US12/321,412; PCT/EE2009/000001).
Zocco D, Zarovni N. Extraction and Analysis of Extracellular Vesicle-Associated miRNAs Following Antibody-Based Extracellular Vesicle Capture from Plasma Samples. Methods Mol. Biol. (2017): 1660:269-285. doi:10.1007/978-1-49397253-1_22
Giacomini E, Vago R, Sanchez AM, Podini P, Zarovni N, Murdica V, Rizzo R, Bortolotti D, Candiani M, Viganò P Secretome of in vitro cultured human embryos contains extracellular vesicles that are uptaken by the maternal side. Sci Rep. (2017) Jul 12;7(1):5210. doi: 10.1038/s41598-017-05549-w
Kooijmans SA, Schiffelers RM, Zarovni N, Vago R. Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment. Pharmacol Res. (2016) Sep;111:487-500. doi:10.1016/j.phrs.2016.07.006
Fais S et al. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine ACS Nano. (2016) Apr 26;10(4):3886-99. doi: 10.1021/acsnano.5b08015
FZarovni N, Corrado A, Guazzi P, Zocco D, Radano G, Muhhina J, Fondelli C, Gavrilova J, Chiesi A. Integrated isolation and quantitative analysis of exosome shuttled proteins and nucleic acids using immunocapture approaches. Methods 2015 Jun 2. doi:10.1016/j.ymeth.2015.05.028